Risk factor
Very high price volatility
Profitability factor
Overvalued vs peers
About
Hangzhou Biotest Biotech Co., LTD. is an enterprise focused on the research, development, manufacturing, sales, and servicing of in vitro diagnostic (IVD) solutions. Operating both domestically within China and across international markets, the company provides a comprehensive range of medical testing products. Their offerings span crucial health areas including reproductive health, cancer detection, cardiovascular conditions, inflammatory markers, biochemical analysis, and various infectious diseases. This extensive portfolio also encompasses rapid diagnostic tests for COVID-19 (covering both antibody and antigen detection), as well as screening kits for drug use (utilizing urine, saliva, and hair samples) and assessing vitamin D levels. Beyond diagnostic kits and reagents, Hangzhou Biotest Biotech also supplies essential accompanying equipment, such as immunochromatography readers and fluorescence immunoassay quantitative analyzers. The company, established in 2008, is based in Hangzhou, China.
Company Valuation
From both historical and forecast perspectives, the stock is overpriced compared to similar stocks. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBITDA